Hypocalcemia in cancer

Abramson, Edith C.; Gajardo, H; Kukreja, Subhash C.

doi:10.1016/0169-6009(90)90259-i

Cited by 22 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More patients in the denosumab group developed hypocalcemia a worrisome event which can cause cardiac and neurological complications, although no such complications were documented in these trials. 57 Denosumab was associated with a decrease in SRE and BTM, and more frequent hypocalcemia, possibly reflecting superior inhibition of osteoclasts compared with zoledronic acid because of a different mechanism of action. 18, 58, 59 …”

Section: Discussionmentioning

confidence: 96%

Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis

Peddi¹,

López-Olivo²,

Pratt³

et al. 2013

Cancer Treatment Reviews

View full text Add to dashboard Cite

Background We conducted a systematic review of the literature to determine the efficacy and safety of denosumab in reducing skeletal-related events (SRE) in patients with bone metastases. Methods A literature search using MEDLINE, EMBASE, Web of Science and The Cochrane Collaboration Library identified relevant controlled clinical trials up-to-March 14, 2012. Two independent reviewers assessed studies for inclusion, according to predetermined criteria, and extracted relevant data. The primary outcomes of interest were SRE, time to first on-study SRE, and overall survival. Secondary outcomes included pain, quality of life, bone turnover markers (BTM), and adverse events. Results Six controlled trials including 6,142 patients were analyzed. Compared to zoledronic acid, denosumab had lower incidence of SRE with a risk ratio (RR) of 0.84 (95% confidence intervals (CI) 0.80-0.88), delayed the onset of first on-study SRE (RR 0.83; 95%CI 0.75-0.90) and time to worsening of pain (RR 0.84; 95%CI 0.77-0.91). No difference was observed in overall survival with pooled hazard ratio of 0.98 (95%CI 0.90-1.0). For total adverse events, denosumab was similar to zoledronic acid (RR 0.97; 95%CI 0.89-1.0). No significant differences were observed in the frequency of osteonecrosis of the jaw (RR 1.4; 95%CI 0.92-2.1). Patients on denosumab had a greater risk of developing hypocalcemia (RR 1.9; 95%CI 1.6-2.3). Conclusions Denosumab was more effective than zoledronic acid in reducing the incidence of SRE, and delayed the time to SRE. No differences were found between denosumab and zoledronic acid in reducing overall mortality, or in the frequency of overall adverse events.

show abstract

Section: Discussionmentioning

confidence: 96%

Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis

Peddi¹,

López-Olivo²,

Pratt³

et al. 2013

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…However, CKD is a condition that can cause hypocalcemia and our finding is in line with authors who associated it with poor prognosis in COVID-19 patients [ 6 ]. Also, some types of cancer presented hypocalcemia [ 31 ] and it is important to monitor calcium level especially when bone-modifying therapies are administered [ 32 ]. This aspect becomes even more important in the case of concomitant Sars-CoV2 infection based on the latest evidence that acute hypocalcemia is an emerging characteristic of osteo-metabolic phenotype in COVID-19 patients [ 33 ].…”

Section: Discussionmentioning

confidence: 99%

Hypocalcemia: A key biomarker in hospitalized COVID-19 patients

et al. 2023

View full text Add to dashboard Cite

“…Patients with primary hyperparathyroidism who are taking cinacalcet should have their drug stopped 48e72 hours before parathyroid surgery to reduce the risk of postoperative hypocalcemia. Hypocalcemia also may occur in patients with bony metastases that induce bone formation, as with prostatic and breast cancer [106].…”

Section: Hypocalcemia Due To Accelerated Skeletal Mineralizationmentioning

confidence: 99%